U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06853886) titled 'Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation' on Feb. 25.
Brief Summary: Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.
Study Start Date: Ap...